Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Norgestimate and Ethinyl Estradiol

×

Overview

What is Tri-Lo-Sprintec?

Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets USP) is a combination oral contraceptive containing the progestational compound norgestimate, USP and the estrogenic compound ethinyl estradiol, USP. Norgestimate, USP is designated as (18,19-Dinor-17-pregn-4-en-20-yn-3-one,17-(acetyloxy)-13-ethyl-, oxime,(17α)‑ (+)-) and ethinyl estradiol, USP is designated as (19-nor-17α-pregna,1,3,5(10)-trien-20-yne-3,17-diol).

The structural formulas are as follows:



What does Tri-Lo-Sprintec look like?



What are the available doses of Tri-Lo-Sprintec?

Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets USP) is available in a blister card. Each blister card contains 28 tablets in the following order ():

What should I talk to my health care provider before I take Tri-Lo-Sprintec?

Nursing mothers: Not recommended; can decrease milk production. ()

How should I use Tri-Lo-Sprintec?

Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. ()

Tri-Lo-Sprintec is dispensed in a blister pack tablet dispenser . Tri-Lo-Sprintec may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration.


What interacts with Tri-Lo-Sprintec?

Sorry No Records found


What are the warnings of Tri-Lo-Sprintec?

Sorry No Records found


What are the precautions of Tri-Lo-Sprintec?

Sorry No Records found


What are the side effects of Tri-Lo-Sprintec?

Sorry No records found


What should I look out for while using Tri-Lo-Sprintec?

Do not prescribe Tri-Lo-Sprintec to women who are known to have the following conditions:


What might happen if I take too much Tri-Lo-Sprintec?

There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.


How should I store and handle Tri-Lo-Sprintec?

Store at 25°C (77°F): excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Keep out of reach of children. Store at 25°C (77°F): excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature]. Keep out of reach of children. Product: 50090-0543NDC: 50090-0543-1 14 TABLET, DELAYED RELEASE in a BOTTLEProduct: 50090-0543NDC: 50090-0543-1 14 TABLET, DELAYED RELEASE in a BOTTLE


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
Do not prescribe Tri-Lo-Sprintec to women who are known to have the following conditions:

See for clinically significant drug interactions with diclofenac.

Thromboembolic Disorders and Other Vascular Problems:

Liver disease:

High blood pressure:

Carbohydrate and lipid metabolic effects:

Headache:

Bleeding Irregularities and Amenorrhea:

The following serious adverse reactions with the use of COCs are discussed elsewhere in labeling:

Adverse reactions commonly reported by COC users are:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).